Immutep Limited (ASX:IMM) Investor Presentation

Immutep Limited (ASX:IMM) Executive Director and CEO Marc Voigt provides an overview of the company, discussing the LAG-3 immune checkpoint, Immutep’s LAG-3 pipeline, eftilagimod alpha’s potential, and ongoing clinical trials.

 

Global leaders in the understanding and development of therapeutics that modulate Lymphocyte Activation Gene-3 or “LAG-3” which is a cell surface molecule which plays a vital role in regulating T cells. LAG-3 was discovered by our Chief Scientific Officer and Chief Medical Officer Dr. Frederic Triebel, putting Immutep at the forefront of immunotherapy drugs for cancer and autoimmune diseases.

IMM’s objective is to harness and strengthen the power of the body’s own immune systems through therapeutic intervention for the benefit of patients’ health. This is how immunotherapy fights cancer and autoimmune disease.

About Finance News Network

Established in 2006, the Finance News Network is one of Australia's largest providers of online business and finance news. Our news is distributed across some of Australia’s most prominent investment platforms. The network connects investors with investment opportunities, the latest ASX news, CEO and fund manager interviews and investor webinars. Keep your finger on the pulse and stay abreast of markets. Tune in to FNN. FNN is a subsidary of Sequoia Financial Group

View more articles by Finance News Network →